Company Profile
Kezar Life Sciences Stock Price, News & Catalysts
- Ticker:
- KZR
- Exchange:
- NASDAQ
- Sector:
- Life Science Tools
- Location:
- United States
Stock performance
7.29 USD (-0.95%)
Close
Last updated: May 8, 2026
53.9M USD
Market cap
Why the stock is moving
Current closing-price context is not available for KZR.
Company overview
Immunology-Focused Biotechnology Company
Kezar Life Sciences has focused on small-molecule therapies for immune-mediated diseases. Following portfolio reductions and operational restructuring, its principal remaining development asset is zetomipzomib.
Zetomipzomib Mechanism
Zetomipzomib is a selective inhibitor of the immunoproteasome, a protein-degradation complex enriched in immune cells. By modulating immunoproteasome activity, the candidate is intended to reduce inflammatory signaling and pathogenic immune-cell activity without broadly suppressing the constitutive proteasome.
Autoimmune Hepatitis Program
The lead indication is relapsed or refractory autoimmune hepatitis, a chronic inflammatory liver disease commonly managed with long-term corticosteroids and other immunosuppressive drugs. Kezar has sought a development strategy that could demonstrate disease control while reducing steroid exposure.
PORTOLA Clinical Evidence
The randomized Phase 2a PORTOLA study evaluated zetomipzomib in patients inadequately controlled by standard therapy. Results supported clinically meaningful steroid-sparing remissions and provided the clinical basis for discussions about a potential global Phase 2b program.
Focused Strategic Position
Kezar discontinued its KZR-261 trial and sold its Sec61 discovery assets, concentrating remaining value on zetomipzomib and associated partnership rights. The company has also been evaluating strategic alternatives for the asset and the broader business.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Kezar Life Sciences (KZR)?
Kezar Life Sciences (KZR) most recently closed at 7.29 USD, a -0.95% move versus the previous session.
What is the market cap of Kezar Life Sciences (KZR)?
Kezar Life Sciences currently has a market capitalization of 53.9M USD on BioPharmSignal.
What does Kezar Life Sciences do?
Immunology-Focused Biotechnology Company Kezar Life Sciences has focused on small-molecule therapies for immune-mediated diseases. Following portfolio reductions and operational restructuring, its principal remaining development asset is zetomipzomib. Zetomipzomib Mechanism Zetomipzomib is a selective inhibitor of the immunoproteasome, a protein-degradation...
On which exchange is KZR stock listed?
Kezar Life Sciences (KZR) is associated with NASDAQ, United States, Life Science Tools.
What is KZR-261?
Focused Strategic Position Kezar discontinued its KZR-261 trial and sold its Sec61 discovery assets, concentrating remaining value on zetomipzomib and associated partnership rights.
Which conditions is Kezar Life Sciences targeting with KZR-261?
Kezar Life Sciences is associated with immunology based on its company overview and current catalyst commentary.
What is Immunology-Focused?
Immunology-Focused Biotechnology Company Kezar Life Sciences has focused on small-molecule therapies for immune-mediated diseases.
What is Biotechnology?
Immunology-Focused Biotechnology Company Kezar Life Sciences has focused on small-molecule therapies for immune-mediated diseases.